{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:54Z","timestamp":1793134134758,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["11\/36\/16"],"award-info":[{"award-number":["11\/36\/16"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The  LOw RISk DCIS (LORIS)\u00a0study was set up to compare conventional surgical treatment with active monitoring in women with ductal carcinoma in situ (DCIS). Recruitment to trials with a surveillance arm is known to be challenging, so strategies to maximise patient recruitment, aimed at both patients and recruiting centres, were implemented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Women aged\u2009\u2265\u200946\u00a0years with a histologically confirmed diagnosis of non-high-grade DCIS were eligible for 1:1 randomisation to either surgery or active monitoring. Prior to randomisation, all eligible women were invited to complete: (1) the Clinical Trials Questionnaire (CTQ) examining reasons for or against participation, and (2) interviews exploring in depth opinions about the study information sheets and film. Women agreeing to randomisation completed validated questionnaires assessing health status, physical and mental health, and anxiety levels. Hospital site staff were invited to communication workshops and refresher site initiation visits to support recruitment. Their perspectives on LORIS recruitment were collected via surveys and interviews.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighty percent (181\/227) of eligible women agreed to be randomised. Over 40% of participants had high anxiety levels at baseline. On the CTQ, the most frequent most important reasons for accepting randomisation were altruism and belief that the trial offered the best treatment, whilst worries about randomisation and the influences of others were the most frequent most important reasons for declining. Most women found the study information provided clear and useful. Communication workshops for site staff improved knowledge and confidence but only about half said they themselves would join LORIS if eligible. The most common recruitment barriers identified by staff were low numbers of eligible patients and patient preference.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Recruitment to LORIS was challenging despite strategies aimed at both patients and site staff. Ensuring that recruiting staff support the study could improve recruitment in similar future trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN27544579, prospectively registered on 22 May 2014<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07703-4","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T08:02:11Z","timestamp":1697270531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Recruiting women with ductal carcinoma in situ to a randomised controlled trial: lessons from the LORIS study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-2483","authenticated-orcid":false,"given":"Sally","family":"Wheelwright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Fairbrother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gaunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pirrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the LORIS Trial Management Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M. S.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Billingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Brace-McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Brookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dodwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fairbrother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hanby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Hoar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Pinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rusby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"issue":"2","key":"7703_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1148\/radiol.211839","volume":"302","author":"LJ Grimm","year":"2022","unstructured":"Grimm LJ, Rahbar H, Abdelmalak M, Hall AH, Ryser MD. Ductal carcinoma in situ: state-of-the-art review. Radiology. 2022;302(2):246\u201355.","journal-title":"Radiology"},{"issue":"3","key":"7703_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/jnci\/djp482","volume":"102","author":"BA Virnig","year":"2010","unstructured":"Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"7703_CR3","unstructured":"NHS Breast Screening Programme, Association of Breast Surgery. An audit of screen detected breast cancers for the screening year April 2020 to March 2021. 2022."},{"issue":"11","key":"7703_CR4","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/bjc.2013.177","volume":"108","author":"MG Marmot","year":"2013","unstructured":"Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205\u201340.","journal-title":"Br J Cancer"},{"key":"7703_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.breast.2016.09.001","volume":"31","author":"EJ Groen","year":"2017","unstructured":"Groen EJ, Elshof LE, Visser LL, Rutgers EJT, Winter-Warnars HAO, Lips EH, et al. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). Breast. 2017;31:274\u201383.","journal-title":"Breast"},{"key":"7703_CR6","doi-asserted-by":"publisher","first-page":"k3322","DOI":"10.1136\/bmj.k3322","volume":"362","author":"B Nickel","year":"2018","unstructured":"Nickel B, Moynihan R, Barratt A, Brito JP, McCaffery K. Renaming low risk conditions labelled as cancer. BMJ. 2018;362:k3322.","journal-title":"BMJ"},{"issue":"1","key":"7703_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.clon.2014.09.015","volume":"27","author":"A Francis","year":"2015","unstructured":"Francis A, Fallowfield L, Rea D. The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol (R Coll Radiol). 2015;27(1):6\u20138.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"16","key":"7703_CR8","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","volume":"51","author":"A Francis","year":"2015","unstructured":"Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015;51(16):2296\u2013303.","journal-title":"Eur J Cancer"},{"issue":"3","key":"7703_CR9","doi-asserted-by":"publisher","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","volume":"9","author":"ES Hwang","year":"2019","unstructured":"Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797.","journal-title":"BMJ Open"},{"issue":"12","key":"7703_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - the LORD study. Eur J Cancer. 2015;51(12):1497\u2013510.","journal-title":"Eur J Cancer"},{"issue":"8","key":"7703_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jjco\/hyx059","volume":"47","author":"C Kanbayashi","year":"2017","unstructured":"Kanbayashi C, Iwata H. Current approach and future perspective for ductal carcinoma in situ of the breast. Jpn J Clin Oncol. 2017;47(8):671\u20137.","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"7703_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1054\/bjoc.2000.1142","volume":"82","author":"V Jenkins","year":"2000","unstructured":"Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer. 2000;82(11):1783\u20138.","journal-title":"Br J Cancer"},{"key":"7703_CR13","volume-title":"State-trait inventory for adults: sampler set, manual, test and scoring key","author":"C Spielberger","year":"1983","unstructured":"Spielberger C. State-trait inventory for adults: sampler set, manual, test and scoring key. Redwood City: Mind Gardens; 1983."},{"issue":"10","key":"7703_CR14","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"6","key":"7703_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD. The Mos 36-item short-form health survey (Sf-36). 1. Conceptual-framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"issue":"1","key":"7703_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41687-020-00189-7","volume":"4","author":"C Shunmugasundaram","year":"2020","unstructured":"Shunmugasundaram C, Rutherford C, Butow PN, Sundaresan P, Dhillon HM. What are the optimal measures to identify anxiety and depression in people diagnosed with head and neck cancer (HNC): a systematic review. J Patient Rep Outcomes. 2020;4(1):26.","journal-title":"J Patient Rep Outcomes"},{"issue":"12","key":"7703_CR17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S1470-2045(12)70503-X","volume":"13","author":"L Fallowfield","year":"2012","unstructured":"Fallowfield L, Francis A, Catt S, Mackenzie M, Jenkins V. Time for a low-risk DCIS trial: harnessing public and patient involvement. Lancet Oncol. 2012;13(12):1183\u20135.","journal-title":"Lancet Oncol"},{"issue":"5","key":"7703_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.breast.2014.06.013","volume":"23","author":"L Fallowfield","year":"2014","unstructured":"Fallowfield L, Matthews L, Francis A, Jenkins V, Rea D. Low grade Ductal Carcinoma in situ (DCIS): how best to describe it? Breast. 2014;23(5):693\u20136.","journal-title":"Breast"},{"key":"7703_CR19","unstructured":"University of Birmingham Cancer Research UK Clinical Trials Unit LORIS. Available from: https:\/\/www.birmingham.ac.uk\/research\/activity\/mds\/trials\/crctu\/trials\/loris\/index.aspx.\u00a0Accessed\u00a09\u00a0Jan\u00a02023."},{"issue":"12","key":"7703_CR20","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1038\/sj.bjc.6606004","volume":"103","author":"V Jenkins","year":"2010","unstructured":"Jenkins V, Farewell D, Batt L, Maughan T, Branston L, Langridge C, et al. The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. Br J Cancer. 2010;103(12):1801\u20137.","journal-title":"Br J Cancer"},{"issue":"5","key":"7703_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/sj.bjc.6602445","volume":"92","author":"V Jenkins","year":"2005","unstructured":"Jenkins V, Fallowfield L, Cox A. The preferences of 600 patients for different descriptions of randomisation. Br J Cancer. 2005;92(5):807\u201310.","journal-title":"Br J Cancer"},{"issue":"2","key":"7703_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.breast.2013.11.009","volume":"23","author":"L Fallowfield","year":"2014","unstructured":"Fallowfield L, Langridge C, Jenkins V. Communication skills training for breast cancer teams talking about trials. Breast. 2014;23(2):193\u20137.","journal-title":"Breast"},{"issue":"7488","key":"7703_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1136\/bmj.38366.562685.8F","volume":"330","author":"V Jenkins","year":"2005","unstructured":"Jenkins V, Fallowfield L, Solis-Trapala I, Langridge C, Farewell V. Discussing randomised clinical trials of cancer therapy: evaluation of a Cancer Research UK training programme. BMJ. 2005;330(7488):400.","journal-title":"BMJ"},{"key":"7703_CR24","first-page":"MR000045","volume":"10","author":"C Houghton","year":"2020","unstructured":"Houghton C, Dowling M, Meskell P, Hunter A, Gardner H, Conway A, et al. Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2020;10:MR000045.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"7703_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12910-021-00585-8","volume":"22","author":"F Gesualdo","year":"2021","unstructured":"Gesualdo F, Daverio M, Palazzani L, Dimitriou D, Diez-Domingo J, Fons-Martinez J, et al. Digital tools in the informed consent process: a systematic review. BMC Med Ethics. 2021;22(1):18.","journal-title":"BMC Med Ethics"},{"key":"7703_CR26","unstructured":"DCIS precision. LORD. Available from: https:\/\/www.dcisprecision.org\/clinical-trials\/lord\/.\u00a0Accessed 9 Jan 2023."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07703-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07703-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07703-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T06:39:11Z","timestamp":1700375951000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07703-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7703"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07703-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LORIS was approved by the West Midland Solihull Ethics Committee (Ref: 14\/WM\/0083) and NHS R&D permissions obtained for each participating centre. The study was sponsored by the University of Birmingham. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"670"}}